Yan-zhi Chen1, Xiao-bing Feng, Zhan-dong Li, Wen-xian Zheng, Hong Sun, Ping-ping Li. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Abstract
OBJECTIVE: To investigate the prognostic influence on long-term overall survival (OS) from treatment with Chinese medicine (CM) and chemotherapy or targeted therapy in advanced non-small-cell lung cancer (NSCLC) patients. METHODS: The clinical data of 206 advanced NSCLC patients who were treated with CM and Western medicine in Beijing Cancer Hospital from April 1999 to July 2013 were retrospectively analyzed. Long-term survivors were defined as OS ≥ 3 years after treatment with CM and chemotherapy. Twenty-eight patients had OS ≥ 3 years, 178 had OS < 3 years, and all clinical data were statistically analyzed with the Cox model. Variables were gender, age, smoking status, performance status (PS) score, pathological type, clinical stage, first-line chemotherapy, targeted therapy, and use of CM. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank sequential inspection. Multivariate survival analysis was used to analyze the meaningful factors of univariate survival analysis with the Cox model. RESULTS: The survival rate of patients with OS ≥ 3 years was 13.6% (28/206). Cox multivariate regression analysis showed that PS score, clinical stage, disease control rate to first-line chemotherapy, and use of CM were independent factors of longterm OS (all <0.05). However, gender, age, smoking, and use of epidermal growth factor receptor tyrosine-kinase inhibitor were not significant (P>0.05). CONCLUSION: PS score, clinical stage, disease control rate to first-line chemotherapy, and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.
OBJECTIVE: To investigate the prognostic influence on long-term overall survival (OS) from treatment with Chinese medicine (CM) and chemotherapy or targeted therapy in advanced non-small-cell lung cancer (NSCLC) patients. METHODS: The clinical data of 206 advanced NSCLCpatients who were treated with CM and Western medicine in Beijing Cancer Hospital from April 1999 to July 2013 were retrospectively analyzed. Long-term survivors were defined as OS ≥ 3 years after treatment with CM and chemotherapy. Twenty-eight patients had OS ≥ 3 years, 178 had OS < 3 years, and all clinical data were statistically analyzed with the Cox model. Variables were gender, age, smoking status, performance status (PS) score, pathological type, clinical stage, first-line chemotherapy, targeted therapy, and use of CM. Univariate survival analysis was performed using the Kaplan-Meier method and log-rank sequential inspection. Multivariate survival analysis was used to analyze the meaningful factors of univariate survival analysis with the Cox model. RESULTS: The survival rate of patients with OS ≥ 3 years was 13.6% (28/206). Cox multivariate regression analysis showed that PS score, clinical stage, disease control rate to first-line chemotherapy, and use of CM were independent factors of longterm OS (all <0.05). However, gender, age, smoking, and use of epidermal growth factor receptortyrosine-kinase inhibitor were not significant (P>0.05). CONCLUSION: PS score, clinical stage, disease control rate to first-line chemotherapy, and use of CM are probably independent prognostic factors for long-term OS in patients with advanced NSCLC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: Liping Lin; Xiaojuan Xiang; He Huang; Hongyun Zhao; Yang Zhang; Jingxun Wu; Yuanyuan Zhao; Xuan Wu; Li Zhang Journal: Zhongguo Fei Ai Za Zhi Date: 2008-06-20
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: M Paesmans; J P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O Van Cutsem; R Sergysels; P Mommen Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544
Authors: Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson Journal: J Thorac Oncol Date: 2015-12-25 Impact factor: 15.609
Authors: Jennifer S Davis; Erin Prophet; Ho-Lan Peng; Hwa Young Lee; Rebecca S S Tidwell; J Jack Lee; Anish Thomas; Eva Szabo; Shine Chang Journal: JNCI Cancer Spectr Date: 2019-04-15